Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms

Our plain-English summary of Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms, by M.G. Mastromarino, V. Aprile, M. Lucchi (Frontiers in Oncology, 2023).

The study

• Authors: M.G. Mastromarino, V. Aprile, M. Lucchi
• Journal: Frontiers in Oncology
• Published: 2023;13:1158416
• Type of article: Editorial
• Cited by: 5 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

In plain English

This article was an editorial, not a research study. It reported no new patients or data of its own. The authors introduced a journal collection of articles on malignant pleural mesothelioma (MPM), a cancer of the pleura, the lining around the lungs. They wrote that the new millennium had seen an outbreak of MPM diagnoses due to the intensive past use of asbestos. They did not discuss fiber types or levels of exposure. They described the estimated survival as less than one year after diagnosis in most cases. They also wrote that ways of diagnosing and treating MPM were still far from standardized. They then briefly described each item in the collection: separate articles by other authors, including research studies and reviews. For example, they wrote that Lauk et al. presented preliminary results on adding bevacizumab to standard induction chemotherapy before MPM surgery. They wrote that Dudnik et al. examined BAP-1 alterations and the results of systemic treatments. The authors concluded that the collection presented new and ongoing research in MPM and reviewed current management strategies.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: editorial introducing a collection (Research Topic) of articles; no original data
• Who was studied: No patients were studied. The editorial introduces a special series of articles by other authors on MPM diagnosis, treatment and molecular mechanisms. The series includes research studies, reviews and a case description.
• Exposure: No exposure was studied. The authors attributed a rise in MPM diagnoses in the new millennium to the intensive past use of asbestos. No fiber types were named.
• Main results:
  • Background statement by the authors, citing other work: estimated survival for MPM is less than one year after diagnosis in most cases.
  • The authors stated that diagnostic and treatment approaches for MPM are still not standardized.
  • The editorial described a separate article in the collection by Lauk et al., which reported preliminary results on adding bevacizumab to standard induction chemotherapy before MPM surgery. This is that article's finding, not this editorial's.
  • The editorial described a separate multi-center study in the collection by Dudnik et al. on BAP-1 alterations and the outcomes of systemic treatments. This is that study's work, not this editorial's.
  • Some items in the collection are reviews rather than original research. For example, Choi et al. provided an updated review on pleural-directed adjuncts in the management of MPM.
• The authors' conclusion: The authors concluded that the articles in the Research Topic provide new and ongoing research in MPM, review current management strategies and updates, and encourage further contributions to the field.

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma.

Related studies

• Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets — I. Cavallari, F. Cerciello, et al. (2023)
• Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma — W. Zhang, X. Wu, et al. (2015)
• Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan — J.A. Gibson, K.E. Finberg, et al. (2021)
• Editorial: Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models — S.K. Lam, S.E. Mutsaers (2022)
• Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis — R. Bruno, G. Alì, et al. (2017)
• Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma — D.H. Sterman, S.M. Albelda (2005)

Browse more research in Frontiers in Oncology, or return to medical research.